PDF-file 137.6kb

PRESS RELEASE
Eurocept Group expands its medical homecare activities with the acquisition of Medizorg
Ankeveen, 22 August 2014
Medizorg (www.medizorg.nl) has been operating since 1995 and developed into a major medical homecare
services company. Medizorg provides care to patients that have been transferred from hospital to their home
environment. Medizorg is based in Houten (NL), operates nationally with specialised nurses, and provides
logistical services and products that are delivered directly at the patient’s home under the hospital's
supervision.
Medizorg provides a broad range of medical homecare treatments including UVB light therapy, injection
therapy, infusion therapy, medical nutrition, diabetes and wound care,.
Medizorg has its own pharmacy and employs more than 100 people.
Eurocept (www.eurocept.nl) is at the forefront of simplifying the care-relationship between doctor and
patient. Through a unique combination of both medical homecare services and qualified nurses (Homecare),
and the distribution capabilities of pharmaceutical products (Pharmaceuticals), Eurocept delivers high-quality
care to patients.
Eurocept Pharmaceuticals is responsible for the development, registration, production, distribution,
marketing and sales of specialty medicines in therapeutical areas that include anesthesia, psychiatry,
urology, pediatrics and immunology. Eurocept Homecare provides specialist medical homecare and
ambulatory medical technology for medicine and medical nutrition at the patient’s home.
Eurocept guarantees in close consultation with the medical specialist the care initiated in the hospital at
home.
By means of its E-care platform, Eurocept is able to give direct feedback on the medical outcomes of the
applied therapy to attending physicians, hospitals, healthcare insurers and pharmaceutical companies.
Eurocept also has an innovative medication spillage module that enable hospitals and pharmacies to re-use
unopened medication in order to reduce cost of medication.
After the proposed acquisition, Eurocept will generate an annual consolidated turnover of around EUR 300
million.
Mike van Woensel (CEO) on this transaction:
"This transaction fits into Eurocept's buy & build strategy which focuses on acquiring pharmaceutical
products/firms and medical homecare companies that operate in the Netherlands and other Northern
European countries.
Medizorg and Eurocept form an obvious and strong combination. Able to provide an even better quality of
service to the medical specialist and patient at an acceptable and transparent cost
Moreover, with many years of experience and the recent innovations that both companies have developed in
ambulatory medical technology and E-care, Eurocept and Medizorg are attractive and reliable partners for
healthcare insurers and hospitals.
The challenge in the coming years will be to keep medical homecare at an acceptable cost level while
further enhancing the quality of service.
Eurocept takes a significant step forward with this acquisition to play a leading role in this field.
The acquisition has been approved by the Dutch Healthcare Authority (NZA) and is subject to approval by
the Dutch Authority for Consumers & Markets (ACM).
For more information:
Brigitte Wijngaarden, Executive Assistant
[email protected]
Telnr.: +31 (0)35 5288377

Download Report